Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 14, 2026, 9:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 62 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Thrombophilia Clear all
Completed Phase 2 Interventional Results available

Study of rADAMTS-13 (SHP655) in the Treatment of Participants With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

NCT03922308
View directory record Official record
Conditions
Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
Interventions
Placebo, SHP655, Standard of Care
Other · Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
7
States / cities
Birmingham, Alabama • Boston, Massachusetts • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2022 · Synced Sep 14, 2026, 9:32 PM EDT
Completed Phase 3 Interventional Results available

Recombinant Human Antithrombin (rhAT) in Patients With Hereditary Antithrombin Deficiency Undergoing Surgery or Delivery

NCT00110513
View directory record Official record
Conditions
Antithrombin III Deficiency
Interventions
Recombinant human antithrombin (rhAT)
Biological
Lead sponsor
rEVO Biologics
Industry
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
3
States / cities
New Haven, Connecticut • St Louis, Missouri • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 16, 2012 · Synced Sep 14, 2026, 9:32 PM EDT
Completed Not applicable Interventional Results available

Tacrolimus and Mycophenolate Mofetil (MMF) in GVHD Prophylactic Regimen Compared to Tacrolimus and Methotrexate (MTX

NCT00360685
View directory record Official record
Conditions
Mucositis, Graft-versus-host Disease
Interventions
Tac+MTX, TAC + MMF
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
Not listed
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 2, 2013 · Synced Sep 14, 2026, 9:32 PM EDT
Completed No phase listed Observational

Biomarker Sub Study of the Compression Stockings to Prevent the Post-Thrombotic Syndrome (SOX) Trial

NCT01615705
View directory record Official record
Conditions
Deep Venous Thrombosis
Interventions
Not listed
Lead sponsor
Sir Mortimer B. Davis - Jewish General Hospital
Other
Eligibility
18 Years and older
Enrollment
803 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
3
States / cities
Detroit, Michigan • Durham, North Carolina • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 10, 2012 · Synced Sep 14, 2026, 9:32 PM EDT
Terminated Phase 2 Interventional Results available

Antithrombin III in Infectious Disease Caused by COVID-19

NCT04899232
View directory record Official record
Conditions
Antithrombin III Deficiency, Covid19
Interventions
Antithrombin III
Drug
Lead sponsor
Enrique Ginzburg
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 6, 2022 · Synced Sep 14, 2026, 9:32 PM EDT
Completed No phase listed Observational

Ceprotin Treatment Registry

NCT01127529
View directory record Official record
Conditions
Protein C Deficiency
Interventions
Protein C Concentrate (Human)
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
Not listed
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
12
States / cities
Phoenix, Arizona • Orange, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Sep 14, 2026, 9:32 PM EDT
Completed Phase 3 Interventional Results available

Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in Thrombotic Thrombocytopenic Purpura (TTP)

NCT00713193
View directory record Official record
Conditions
Thrombotic Thrombocytopenic Purpura
Interventions
Cyclosporine, Prednisone
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 2, 2023 · Synced Sep 14, 2026, 9:32 PM EDT
Completed No phase listed Observational

Study of Abnormal Blood Clotting in Children With Stroke

NCT00001927
View directory record Official record
Conditions
Abnormalities, Blood Coagulation Disorder, Brain Disease, Cerebrovascular Accident, Vascular Disease
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Up to 45 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 14, 2026, 9:32 PM EDT
Recruiting Phase 3 Interventional

Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass

NCT06096116
View directory record Official record
Conditions
Acquired Antithrombin Deficiency
Interventions
Human plasma derived antithrombin, Placebo
Drug
Lead sponsor
Octapharma
Industry
Eligibility
18 Years to 85 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
9
States / cities
Stanford, California • Miami, Florida • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Sep 14, 2026, 9:32 PM EDT
Terminated Phase 3 Interventional Results available

Evaluating the Effectiveness of Adding Rituximab to Standard Treatment for Thrombotic Thrombocytopenic Purpura (TTP)

NCT00799773
View directory record Official record
Conditions
Thrombotic Thrombocytopenic Purpura
Interventions
Rituximab, Plasma exchange, Corticosteroids
Drug · Procedure
Lead sponsor
Carelon Research
Other
Eligibility
12 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
23
States / cities
Birmingham, Alabama • Atlanta, Georgia • Iowa City, Iowa + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2013 · Synced Sep 14, 2026, 9:32 PM EDT
Completed Phase 3 Interventional Results available

Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)

NCT02878603
View directory record Official record
Conditions
Acquired Thrombotic Thrombocytopenic Purpura
Interventions
Caplacizumab, Standard of Care
Biological · Other
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
8
States / cities
St Louis, Missouri • Valhalla, New York • Durham, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2022 · Synced Sep 14, 2026, 9:32 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura

NCT04683003
View directory record Official record
Conditions
Thrombotic Thrombocytopenic Purpura (TTP)
Interventions
TAK-755
Biological
Lead sponsor
Takeda
Industry
Eligibility
0 Years to 70 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
5
States / cities
Atlanta, Georgia • Buffalo, New York • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Sep 14, 2026, 9:32 PM EDT
Completed Phase 3 Interventional

TIPPS: Thrombophilia in Pregnancy Prophylaxis Study

NCT00967382
View directory record Official record
Conditions
Pregnancy, Thrombophilia, Pregnancy Complications
Interventions
dalteparin sodium
Drug
Lead sponsor
Ottawa Hospital Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2014
U.S. locations
2
States / cities
St Louis, Missouri • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 18, 2014 · Synced Sep 14, 2026, 9:32 PM EDT
Recruiting No phase listed Observational

Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)

NCT01257269
View directory record Official record
Conditions
Thrombotic Thrombocytopenic Purpura, Congenital Thrombotic Thrombocytopenic Purpura, Familial Thrombotic Thrombocytopenic Purpura, Thrombotic Thrombocytopenic Purpura, Congenital, Upshaw-Schulman Syndrome
Interventions
Observation
Other
Lead sponsor
Insel Gruppe AG, University Hospital Bern
Other
Eligibility
Not listed
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2030
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Sep 14, 2026, 9:32 PM EDT
Completed No phase listed Observational

Coagulation Changes Associated With COVID-19 Infection

NCT04460664
View directory record Official record
Conditions
COVID, Disseminated Intravascular Coagulation, Coagulation Disorder
Interventions
Quantra System
Diagnostic Test
Lead sponsor
HemoSonics LLC
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated May 12, 2022 · Synced Sep 14, 2026, 9:32 PM EDT
Completed Phase 3 Interventional Results available

Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura

NCT02553317
View directory record Official record
Conditions
Acquired Thrombotic Thrombocytopenic Purpura
Interventions
Caplacizumab, Placebo
Biological
Lead sponsor
Ablynx, a Sanofi company
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • Atlanta, Georgia + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Sep 14, 2026, 9:32 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Novel Experimental COVID-19 Therapies Affecting Host Response

NCT04924660
View directory record Official record
Conditions
COVID-19, SARS-CoV-2 Infection, Coronavirus Infection
Interventions
TXA127, TRV027, Placebo, Fostamatinib
Drug
Lead sponsor
Sean Collins
Other
Eligibility
18 Years and older
Enrollment
1,060 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
51
States / cities
Birmingham, Alabama • Chandler, Arizona • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2025 · Synced Sep 14, 2026, 9:32 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Guilford Genomic Medicine Initiative (GGMI)

NCT01372553
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer, Colon Cancer, Thrombophilia
Interventions
Not listed
Lead sponsor
The Moses H. Cone Memorial Hospital
Other
Eligibility
18 Years and older
Enrollment
1,184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Greensboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 15, 2014 · Synced Sep 14, 2026, 9:32 PM EDT
Withdrawn No phase listed Observational

The Role of Microparticles as a Biomarker

NCT02626663
View directory record Official record
Conditions
Atypical Hemolytic Uremic Syndrome, Thrombotic Thrombocytopenic Purpura, Microparticles, Microangiopathic Hemolytic Anemia
Interventions
Not listed
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 18, 2019 · Synced Sep 14, 2026, 9:32 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

A Comparison of Sequential Compression Devices and Foot Pumps in the Obstetric Population

NCT00356434
View directory record Official record
Conditions
Thrombophilia
Interventions
Kendall A-V foot impulse pump, model 6060, Kendall sequential compression device, model 9525
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Sep 14, 2026, 9:32 PM EDT
Completed Phase 3 Interventional Results available

Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura

NCT05468320
View directory record Official record
Conditions
Thrombotic Thrombocytopenic Purpura
Interventions
Caplacizumab, Corticosteroids, anti-CD20 antibody
Drug · Biological
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Birmingham, Alabama • Baltimore, Maryland • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Sep 14, 2026, 9:32 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Thromboelastography to Assess Age-Related Coagulation Differences in Patients Undergoing Cesarean Delivery

NCT01416454
View directory record Official record
Conditions
Thrombophilia
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 21, 2013 · Synced Sep 14, 2026, 9:32 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of ART-123 in Subjects With Sepsis and Disseminated Intravascular Coagulation

NCT00487656
View directory record Official record
Conditions
Sepsis, Disseminated Intravascular Coagulation
Interventions
ART-123, placebo
Drug
Lead sponsor
Artisan Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
49
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tuscon, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated May 17, 2011 · Synced Sep 14, 2026, 9:32 PM EDT
Completed Phase 2Phase 3 Interventional

Efficacy and Safety Study of Protein C Concentrate in Subjects With Severe Congenital Protein C Deficiency

NCT00157118
View directory record Official record
Conditions
Protein C Deficiency
Interventions
Protein C Concentrate (Human) Vapor Heated
Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
Not listed
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
12
States / cities
Los Angeles, California • Denver, Colorado • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Sep 14, 2026, 9:32 PM EDT